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Abstract: Tardive dyskinesia (TD) is a hyperkinetic movement disorder caused by the use
of dopamine receptor-blocking agents (DRBAs), a category of medications that includes
first- and second-generation antipsychotics (APs) and agents such as metoclopramide that are
used for the treatment of nausea and gastrointestinal dysmotility. While TD can affect people
of all ages, older age is associated with increased risk of TD and also with the emergence of
TD occurring after shorter treatment durations and lower dosages of DRBAs. TD is char
acterized by involuntary movements that include the face, limbs, and trunk, and is associated
with increased comorbidities, social stigmatization, and impaired physical and mental health.
Once present, TD tends to persist despite AP dose adjustment or discontinuation. Even with
the use of US Food and Drug Administration (FDA)-approved medications for TD, symp
toms may persist. Because the leading hypothesis for the pathophysiology of TD has been
dysregulation of dopamine transmission due to treatment with DRBAs, APs that avoid
postsynaptic dopamine receptor blockade may provide an alternative therapeutic approach
for patients who require an AP. In this review, we discuss the risks, burdens, prevention, and
management of TD, with a focus on older people.
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Tardive dyskinesia (TD) is a hyperkinetic movement disorder caused by dopamine
receptor-blocking agents (DRBAs), a category of medications that includes anti
psychotics (APs) and some agents used to treat nausea and gastrointestinal dysmo
tility, such as metoclopramide.1 The Diagnostic and Statistical Manual of Mental
Disorders, 5th edition, defines TD as involuntary athetoid or choreiform move
ments. Symptoms must last for at least a few weeks and develop in association with
the use of a neuroleptic medication for at least a few months.2 TD is often
irreversible, can impact daily life, and can be socially stigmatizing.3 While all
individuals treated with DRBAs are at risk for developing TD, older individuals
are at higher risk and particularly vulnerable to developing this disorder, even after
shorter exposure to newer second-generation APs.4–7
In addition to their US Food and Drug Administration (FDA)-approved indica
tions, APs have also been used for non-approved (ie, “off-label”) indications,7
including neuropsychiatric symptoms associated with Parkinson’s disease or
dementia. The increasing and widespread use of APs has led to more elderly people
being placed at risk of TD.8–11 Moreover, older individuals on APs may face
a greater risk for complications related to TD, as they are more prone to falls,
orthostatic hypotension, somnolence, and generally have a greater burden of
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comorbidities than younger people.12–16 The aim of this
review is to examine the risk, burden, and management of
TD with a particular focus on the elderly.
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Overview of Tardive Dyskinesia
TD is characterized by a delayed onset of involuntary motor
movements in the face, trunk, and limbs after exposure to
DRBAs.4,17 Involuntary movement are classically peri-oral,
including grimacing, tongue protrusion, and lip puckering,
but also include neck, shoulder, and limb movements.18 In
some cases, symptoms can be severe enough to interfere
with breathing, speaking, eating, and ambulation.19,20
TD is often irreversible and can impose long-lasting bur
dens on psychosocial, physical, and economic health.4,21–23
Historically, assumptions that those afflicted are unaware of
their symptoms or unconcerned with them have obscured
these burdens, especially among persons with schizophrenia
who can have limited insight into their physical and mental
health.24,25 However, a recent study of those with a history of
AP use for the treatment of schizophrenia, schizoaffective
disorder, mood disorder, and other psychiatric disorders,
found that nearly 80% of subjects with a clinician-confirmed
diagnosis of possible TD reported noticing recent involuntary
movements.21 Many of these individuals also felt that the
uncontrollable movements impacted their ability to engage
in daily activities, talk, or socialize.21
The degree to which those with TD experience reduced
general health, life enjoyment and satisfaction, and
enhanced social withdrawal is generally proportional to
the severity of the symptoms.3 The disorder can impact
leisure activities or the willingness to participate in com
munity activities. TD can also hinder the ability to find and
maintain employment due to the symptoms themselves or
embarrassment caused by the symptoms.21,26 The financial
impact of TD on the healthcare system can be consider
able, as reported in a large, retrospective analysis that
found that people with both TD and schizophrenia, mood
disorders, or other psychiatric disorders experience 29%
more hospital admissions, 5% more outpatient visits, and
21% more emergency room visits than those without
TD.22 This results in a nearly doubling of the healthcarerelated financial burden for individuals with TD from
$28,777 to $54,656 over a 2-year period.22

Prevalence and Risk of TD
The mean prevalence of TD in people treated with APs
was 20–25% according to meta-analyses of articles pub
lished between 1959 and 2015.27,28 A 20-year longitudinal
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study initiated prior to the widespread use of secondgeneration APs calculated a yearly cumulative incidence
of TD of 4%–5%.27 The frequent occurrence of TD and
acute extrapyramidal symptoms, such as drug-induced
parkinsonism and acute dystonia, encouraged the develop
ment of second-generation APs, which were intended to
minimize the incidence of adverse neurological effects.
Although acute drug-induced parkinsonism and acute dys
tonia are lessened, TD has not been eliminated. The annual
prevalence of TD among patients receiving APs was esti
mated to be 7.6 to 9.7 per 1000 people according to a large
retrospective observational study of electronic health
records, with nearly 80% of study participants
using second-generation APs.15 A direct comparison of
annualized incidence between first- and secondgeneration APs indicates a reduced but not eliminated
risk of TD with use of second-generation APs (range of
0.8% to 3% with use of second-generation APs vs 5.4% to
7.7% with use of first-generation APs).6,29
The most important risk factors for the development of
TD include older age and cumulative exposure to the
DRBA. Other risk factors include the dopamine-receptor
binding affinity of the DRBA in question, female sex,
mood disorders, dementia, and prior drug-induced
parkinsonism.4,30–33 Smoking and substance abuse may
also be associated with a higher risk of developing TD.33

TD in Older Populations
As noted, age is a key risk factor for developing TD.31,34
A study of 404 people aged ≥55 years reported cumulative
TD incidences of 26%, 30%, and 60% after the first, second,
and third year, respectively, of first-generation AP use.35 This
is considerably higher than that observed in younger people;
a meta-analysis of 32 randomized studies that included
10,706 subjects of mixed ages calculated an annualized TD
incidence of 6.5% with the use of first-generation APs.28
Second-generation APs offer older people a reduced risk of
approximately 6% and 7% after the first year of use to 11%
after the second year of use in those who are naïve to firstgeneration APs. However, the risk (nonetheless remains
higher than the incidence of ≤3% observed among younger
adults treated with second-generation APs.29,36 Although TD
risk increases in a dose-dependent manner, older patients are
susceptible after exposure to even low doses of secondgeneration APs.4,37 A study of 255 older patients with
dementia (mean age: 82.5 years) found that 1.7% of patients
treated daily with 0.75 to 1.5 mg risperidone for 1 year
developed TD; in contrast, no new cases of TD were reported
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in a mixed-age adult population of 541 patients treated with
a mean dose of risperidone 3.9 mg/day for 6 months.37,38
Similarly, no change from baseline was observed in TD
symptoms among adults aged ≤65 years after 1 year of 4 to
10 mg risperidone daily.39 The mechanism underlying agerelated increased susceptibility is unclear but may be due to
higher cumulative exposure to APs as well as an age-related
decrease in dopaminergic neurons in the substantia nigra.40
Because APs are sometimes used off-label for demen
tia-related psychosis and aggression,8,11 TD can be
encountered in this population, particularly within facil
ities that care for older people. Up to 33% of patients
residing in nursing homes or assisted living facilities
receive APs, predominantly for off-label indications.8
A survey of 350,000 nursing home residents in 8 states,
representing 40% of residents nationally, found that in
2006, 27.6% of residents had taken APs in the last 7
days, and only 20.7% of these were for treatment of the
primary indications of schizophrenia or bipolar disorder.41
The National Nursing Home Survey of 300,000 residents
found that 23% of respondents had received at least
1 second-generation AP, and 86.3% of these prescriptions
were for off-label indications.42 Dementia is one of the
most common indications for off-label AP use in these
facilities, despite the bolded “black box” warning against
AP use in patients with dementia-related psychosis.8,11
Behavioral issues related to dementia may in part drive
AP use in this population. Crystal et al found that half of
residents with dementia and aggressive behavior received
AP treatment, while 40% and 23% of patients with non
aggressive dementia or dementia without behavioral symp
toms, respectively, also received APs.41 Other common
reasons for off-label AP use among older people are anxi
ety and insomnia.8 The prevalence of off-label AP use,
particularly among older individuals, has prompted the
Centers for Medicare and Medicaid Services to issue
guidelines and fact sheets recommending against this
practice,43 and long-term care settings are compelled to
adhere to efforts to mitigate their use. However, recent
studies suggest AP use outside of approved indications
continues.44,45

Impact of TD in Older People
The impact of TD on an individual’s physical, mental, and
economic health may intensify with age.3,22 The social and
emotional effects of symptoms are highly debilitating for
people with TD of all ages, but feelings of isolation and
depression may be especially profound for older
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people.3,16 Older individuals are also uniquely vulnerable
to the physical consequences of TD, such as impaired gait
and balance, which can lead to falls.16,26 TD in older
patients often presents as oro-bucco-lingual dyskinesia,
and these movements can interfere with eating and swal
lowing; incidents of choking resulting from respiratory TD
have been reported.7,19,46 Further, oro-bucco-lingual TD
can cause loosening of natural and artificial teeth and be
augmented by edentulousness and denture use; edentulous
ness itself can cause abnormal movements of the mouth in
the absence of neurological disorders such as TD.26,46,47
Older patients may also be affected by dyskinesias of the
limbs, trunk, and respiratory system, with symptoms such
as grunting.7,26,48
The observation that older people with TD are also at
increased risk of cardiac, metabolic, and other movement
disorder comorbidities complicates treatment of TD in
these patients.12–15 Lastly, the high healthcare utilization
costs associated with TD are likely to severely tax the
resources of older people on fixed or limited incomes
and stress the healthcare system in general.22 Given these
considerable impacts, treatment plans for older individuals
with psychiatric conditions should include modification of
prescribing practices to minimize the risk of TD.

Mechanisms of TD with APs
Understanding the pathophysiology of TD is essential to
choosing therapies for psychiatric conditions that mini
mize the risk of this disorder in older patients. While
there is not a universally accepted mechanism through
which APs drive the development of TD, a leading
hypothesis revolves around the dysregulation of dopami
nergic transmission.49,50 Antagonism of postsynaptic
dopamine D2 receptors in the mesolimbic pathway, speci
fically in the ventral striatum, drives efficacy of APs in
reducing positive symptoms associated with psychosis.
However, long-term blockade of D2 receptors in the
nigrostriatal pathway, specifically in the dorsal striatum,
can lead to an increase in the number and function of
postsynaptic dopamine D2 receptors (often referred to as
the “supersensitivity” or “hypersensitivity” hypothesis)
subsequently
interfering
with
voluntary
motor
4,51,52
control.
This enhanced sensitivity to dopamine in
the dorsal striatum can lead to several types of motor
symptoms, including TD. Genetic studies in support of
a role for dopamine hypersensitivity in TD include obser
vations that mutations in the PIP5K2A and DRD2 dopa
mine receptor genes and in the glycine variant of the
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dopamine D3 receptor have been linked to the develop
ment of TD in people with schizophrenia.53–55
Second-generation APs are thought to carry a lower risk
for the development of TD compared with first-generation
APs because although both types of APs are
DRBAs, second-generation APs are also antagonists at pre
synaptic serotonin 5-HT2A receptors, which can lessen the
risk of drug-induced movement disorders in general. In addi
tion, some second-generation APs have a lower binding
affinity to the postsynaptic dopamine receptor as well.18,56,57
Investigational uses of functional magnetic resonance
imaging (fMRI) to help elucidate the pathophysiology of
TD are also of interest. For example, two recent reports
demonstrated statistically significant differences in gray mat
ter volume and resting state functional connectivity of motorrelated brain regions of interest in patients with schizophrenia
treated with antipsychotics with and without a TD diagnosis.
Gray matter volumes of the brainstem, inferior frontal and
precentral gyri, cuneus, and lingual gyrus were significantly
different in patients with TD than in those without.58
Similarly, patients with TD exhibited a reduction in resting
state functional connectivity between the right postcentral
gyrus and the inferior frontal gyrus of the left triangular
part compared with patients without TD.59 Gray matter
volumes of the cuneus and lingual gyrus and the reduction
in resting state functional connectivity observed were also
correlated with TD severity, as assessed by the total score on
the Abnormal Involuntary Movement Scale, providing
further support that changes in gray matter volume or func
tional connectivity may be related to the pathophysiology of
TD.58,59 The use of fMRI in evaluating TD remains investi
gational, and its relevance in older populations deserves
further study.

Strategies for Minimizing TD Risk
TD can be irreversible, highlighting the need for preventative
strategies. Many clinicians focus primarily on limiting the use
of TD-inducing medications and secondarily on detecting TD
symptoms early.51,60,61 Considering the pharmacology of indi
vidual APs with an understanding of proposed TD pathophy
siology informs the selection of therapies that are least likely to
induce TD. Use of less potent dopamine receptor
blocking second-generation APs instead of first-generation
APs may reduce TD risk. Correll and colleagues presented
the initial support for a lower risk of TD associated
with second-generation APs compared with first-generation
APs in a meta-analysis of 11 randomized studies.6 Here, the
annual TD risk estimate associated with haloperidol was 5.4%
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across 3 studies, whereas across 5 studies, the risk estimates
associated with olanzapine, risperidone, quetiapine, or amisul
pride ranged from 0.5% to 1.5%. In addition, because older
people both experience benefit from second-generation APs at
low doses and are at greater risk of developing TD after
minimal exposure, treatment regimens should reflect these
sensitivities and implement the lowest effective AP dose.7,62
Several nondopaminergic approaches to treat psychosis
are also in development. Serotonin receptor inhibition has
not been associated with TD, and selective inverse agon
ism/antagonism of 5HT receptors may be a therapeutic
strategy that would mitigate the risk of TD.63 Another
potential preventative strategy is treatment of psychiatric
disorders through selective agonism of the trace amineassociated receptor 1 (TAAR1), an approach that has
recently been shown to improve symptoms of schizophre
nia in adults and does not induce motor abnormalities in
animal models.64 Targeting the muscarinic system with
a combination of xanomeline and trospium has also been
proposed as a nondopaminergic strategy for mitigating TD
risk.65,66

Current Therapeutic Strategies for TD in
Older Patients
The first step in developing the optimal treatment strategy
for TD is timely diagnosis, which requires the clinician to
be routinely vigilant.67 Diagnosis is based on history of
exposure to DRBAs, and a minimum duration of only 1
month of AP exposure is required to diagnose TD in
individuals aged ≥60 years, compared with 3 months in
younger adults.2,7,60
An early strategy to mitigate TD symptoms involves
modification of the existing AP medication regimen if
clinically feasible.68 However, success with this
approach is often limited.23,68,69 Two vesicular monoa
mine transporter 2 (VMAT2) inhibitors, valbenazine and
deutetrabenazine, have been approved by the US FDA
to treat TD.68,70,71 Recent guidelines for the treatment of
schizophrenia recommend VMAT2 inhibitors as firstline therapy for patients who have moderate to severe
or disabling TD or for patients with mild TD on the
basis of such factors as patient preference, associated
impairment, or effect on psychosocial functioning.72 In
two recent studies of subjects aged ≥55 years who had
participated in clinical trials conducted by the manufac
turer, Sajatovic et al demonstrated that valbenazine
(median: 61 years, range: 55–84 years) and
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deutetrabenazine (mean age: 63.1 years, range: 55–81
years are well tolerated in older individuals.73,74 Of
note, VMAT2 inhibition manages the symptoms of TD
but does not cure them; dyskinetic movements generally
return when the VMAT2 inhibitor is discontinued.75
Although anticholinergic agents may effectively treat
acute drug-induced parkinsonism, these medications can
worsen TD.23 Anticholinergic drug burden is also associated
with impaired cognition. Discontinuation of anticholinergic
medication leads to an improvement of TD symptoms in
approximately 60% of people, and if enacted, should be
done gradually.23,76 An additional benefit from deprescribing
anticholinergic medication would be a lessening of the mem
ory impairment and other anticholinergic adverse effects
associated with this class of drug.77
Avoiding TD by eliminating exposure to DRBAs may
be the best option for older persons. Several novel agents
are being studied for their antipsychotic properties.
Alternative mechanisms, including serotonin inverse agon
ism/antagonism in the absence of dopamine receptor
blockade, agonism of TAAR1 receptors, and modulation
of muscarinic cholinergic receptors, may provide different
therapeutic approaches for patients who require
a medication with an AP effect and avoid contributing to
the risk of developing TD.63–66

Conclusion
TD is a particular concern for elderly individuals treated
with DRBAs, including second-generation APs. The pre
valence of TD in this population is up to 5 to 6 times that
of younger people and is encountered clinically in part
because of the off-label prescription of APs for dementiarelated behavioral and psychological disorders.7,11 In addi
tion to the TD symptoms themselves, older people may be
more severely impacted by associated comorbidities and
impaired physical and mental health.13–15,78
Although the recent approval of VMAT2 inhibitors pro
vides a new therapeutic option once TD occurs, avoiding this
often irreversible movement disorder would be preferred. An
important strategy for mitigating TD risk is prescribing APs
that address psychiatric conditions while minimizing the risk
of developing this disorder. Currently, second-generation
APs are recommended over first-generation APs.23
However, the risk of TD among older individuals persists at
a rate of approximately 6% with use of second-generation
APs.36 Newer APs that are effective in treating mental health
disorders but that do not block postsynaptic dopamine D2
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receptors in the dorsal striatum, and thus do not carry
a significant risk for TD, are needed.
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APs, antipsychotics; DRBAs, dopamine receptor-blocking
agents; FDA, Food and Drug Administration; TD, tardive
dyskinesia; VMAT2, vesicular monoamine transporter 2.
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